1-4 of 4
A. Ferrant, MD
Close
Sort by
Journal Articles

Palifermin Treatment in Patients Receiving High Dose Melphalan or BEAM Prior to Autologous Peripheral Blood Stem-Cell Transplantation.

Anne Sonet, MD, G. Bries, MD, N. Meulemans, MD, A. Van Hoof, MD, E. Steel, MD, M. André, MD, A. Ferrant, MD, N. Straetmans, MD, P. Zachée, MD, V. Robin, MD, H. Demuynck, MD, L. Noens, MD, A. Bosly, MD, M. Delforge, MD, D. Bron, MD
Journal: Blood
Blood (2006) 108 (11): 5241.
https://doi.org/10.1182/blood.V108.11.5241.5241
Published: 2006
Journal Articles

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.

L. Ades, MD, M. Sanz, MD, S. Chevret, MD, S. De Botton, MD, G. Martin, MD, E. Raffoux, MD, E. Vellenga, MD, A. Guerci, MD, M. Gonzalez, MD, A. Pigneux, MD, C. Rayon, MD, A.M. Stoppa, MD, J. De la Serna, MD, T. Pabst, MD, S. Meyer-Monard, MD, R. Parodi, MD, J. Bergua, MD, F. Rigal-Huguet, MD, A. Vekhoff, MD, S. Negri, MD, N. Fegueux, MD, A. Ferrant, MD, D. Bron, MD, H. Dombret, MD, L. Degos, MD, P. Fenaux, MD
Journal: Blood
Blood (2005) 106 (11): 544.
https://doi.org/10.1182/blood.V106.11.544.544
Published: 2005
Journal Articles

Allogeneic (Allo-) or Autologous (Auto-) Peripheral Blood Stem Cell Transplantation (SCT) Randomized Versus a Second Intensive Consolidation after a Common Induction and Consolidation Course in Patients with Bad Prognosis Myelodysplastic Syndromes and Acute Myelogenous Leukemia Following MDS of More Than 6 Months Duration: The Final Analysis of a Joint Study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups.

T.M. De Witte, MD, A. Hagemeijer, MD, S. Suciu, PhD, A. Belhabri, MD, M. Delforge, MD, C. Aul, MD, M. Aivado, MD, D. Selleslag, MD, H. Schouten, MD, A. Ferrant, MD, H. Biersack, MD, S. Amadori, MD, P. Muus, MD, U. Jehn, MD, F. Beeldens, J. Jansen, PhD, E. Hellstrom-Lindberg, MD, T. Kovacsovics, MD, U. Hess, MD, P. Wijermans, MD, G. Ossenkoppele, MD, A. Gratwohl, MD, J.-P. Marie, MD, R. Willemze, MD
Journal: Blood
Blood (2005) 106 (11): 794.
https://doi.org/10.1182/blood.V106.11.794.794
Published: 2005
Journal Articles

A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups.

M. Oosterveld, MD, S. Suciu, M.Sc, P. Muus, MD, M. Delforge, MD, A. Belhabri, MD, C. Aul, MD, D. Selleslag, MD, A. Ferrant, MD, J.-P. Marie, MD, S. Amadori, MD, U. Jehn, MD, U. Hess, MD, R. Willemze, MD, E. Hellstrom-Lindberg, MD, M. Vignetti, MD, B. Labar, MD, F. Mandelli, MD, T. De Witte, MD
Journal: Blood
Blood (2004) 104 (11): 2020.
https://doi.org/10.1182/blood.V104.11.2020.2020
Published: 2004